Subscribe to RSS
DOI: 10.1055/s-0044-1786012
The Role of 68Ga PSMA Imaging in Evaluating Adrenal Lesions in Prostate Cancer Patients
Abstract
Objectives Gallium-68 prostate-specific membrane antigen (68Ga-PSMA) imaging is valuable for staging because an accurate diagnosis, metastatic or nonmetastatic for prostate cancer patients, is required for deciding to treatment approaches and prognostic assessment. The aim of this study was primarily to distinguish between benign and metastatic adrenal gland lesions detected during 68Ga-PSMA positron emission tomography (PET)/CT imaging, to evaluate the presence of factors predicting its development, and then to determine the life expectancy of patients with metastatic adrenal lesions.
Materials and Methods We performed a database search for PET/CT records generated from June 2016 to February 2021 for “adrenal gland” in report for patients who underwent 68Ga-PSMA examination with prostate cancer patients.
Results Twenty-three patients (10 benign and 13 metastatic) were included in this study. The total prostate-specific antigen, adrenal gland size, adrenal gland density, and maximum standardized uptake (SUVmax) values are significantly different between groups (p < 0.05). On receiver operating characteristic curve analysis, the SUVmax cutoff value > 6.8 provided both sensitivity and specificity of 100%. However, with 29 mm as the adrenal gland size cutoff and 21.2 as Hounsfield unit, the sensitivity and specificity were 56.2 and 92.3%, and 93.8 and 92.3%, respectively. The survival of the benign and metastatic groups was compared and a statistically significant difference was found (p = 0.006). The presence of pelvic lymph nodes was statistically negatively affected the surveillance between the groups.
Conclusion The presence of atypical metastases such as adrenal gland is not insignificant in prostate cancer patients. Because of this degree of impact on patient management, accurate staging by imaging with 68Ga-PSMA should be an integral part of prostate cancer management.
Publication History
Article published online:
23 April 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
- 2 Mottet N, Cornford P, van den Bergh RCN. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer 2022. Accessed May 1, 2022 at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelines-on-Prostate-Cancer-2022_2022–04–25–063938_yfos.pdf
- 3 Hess KR, Varadhachary GR, Taylor SH. et al. Metastatic patterns in adenocarcinoma. Cancer 2006; 106 (07) 1624-1633
- 4 Gandaglia G, Karakiewicz PI, Briganti A. et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol 2015; 68 (02) 325-334
- 5 Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 2018; 38 (01) 200-217
- 6 Perera M, Papa N, Roberts M. et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 2020; 77 (04) 403-417
- 7 Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol (Oxf) 2002; 56 (01) 95-101
- 8 Gandaglia G, Abdollah F, Schiffmann J. et al. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 2014; 74 (02) 210-216
- 9 Vinjamoori AH, Jagannathan JP, Shinagare AB. et al. Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol 2012; 199 (02) 367-372
- 10 Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med 2008; 132 (06) 931-939
- 11 de la Monte SM, Moore GW, Hutchins GM. Metastatic behavior of prostate cancer. Cluster analysis of patterns with respect to estrogen treatment. Cancer 1986; 58 (04) 985-993
- 12 Epstein JI, Zelefsky MJ, Sjoberg DD. et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 2016; 69 (03) 428-435
- 13 Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol 2014; 65 (01) 3-6
- 14 Roach PJ, Francis R, Emmett L. et al. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med 2018; 59 (01) 82-88
- 15 Shah RB, Mehra R, Chinnaiyan AM. et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64 (24) 9209-9216
- 16 Bubendorf L, Schöpfer A, Wagner U. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31 (05) 578-583
- 17 Bazhenova L, Newton P, Mason J, Bethel K, Nieva J, Kuhn P. Adrenal metastases in lung cancer: clinical implications of a mathematical model. J Thorac Oncol 2014; 9 (04) 442-446